Soluble, thrombin-related material in arterial thrombi and plasma studied during catheter-directed intra-arterial thrombolysis

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 2, 1999, Pages 87-91

  Sandbaek, Gunnar ^a   Bjornsen S ^b   Brosstad, F ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NONE

Author keywords

Alteplase; Catheter directed; Fibrinopeptide A; Thrombin; Thrombin antithrombin complex; Thrombolytic therapy; Thrombus

Indexed keywords

ALTEPLASE; FIBRINOPEPTIDE A; HEPARIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANGIOGRAPHY; ARTERY CATHETERIZATION; ARTERY THROMBOSIS; BLOOD SAMPLING; CLINICAL ARTICLE; ENZYME IMMUNOASSAY; FEMALE; FIBRINOLYTIC THERAPY; HEMATOLOGICAL PARAMETERS; HUMAN; LEG BLOOD FLOW; LEG ISCHEMIA; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0033006640     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199903000-00005     Document Type: Review

References (11)

1. 1. Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230.
2. 2. Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992; 85: 928-934.
3. 3. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25: 203-209.
4. 4. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097.
5. 5. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106.
6. 6. Nossel HL, Yudelman I, Canfield RE, Butler VP Jr, Spanondis K, Wilner GD, et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
7. 7. Clauss A. Gerinnungsphysiologische Schnellmetode zur Bestimmung ses Fibrinogens. Acta Haematologica 1957; 17: 237-246.
8. 8. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-552.
9. 9. Herren T, Stricker H, Haeberli A, Do DD, Straub PW. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation 1994; 90: 2679-2686.
10. 10. Garcia-Avello A, Garcia-Frade LJ, Gandarias C, Ocana J, Cancelas JA, Lasso M. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res 1994; 73: 109-115.
11. 11. Zaugg H. Thromboplastic activity of human arterial walls and its interaction with the plasmatic coagulation system. J Clin Chem Clin Biochem 1980; 18: 545-549.